LOC105374945: A Potential Drug Target and Biomarker (G105374945)
LOC105374945: A Potential Drug Target and Biomarker
Abstract:
LOC105374945 (Uncharacterized LOC105374945, transcript variant X1) is a non-coding RNA molecule that has been identified as a potential drug target and biomarker. It is a key regulator of the cell cycle, and its dysfunction has been linked to various diseases, including cancer. This article discusses the potential implications of LOC105374945 as a drug target and biomarker, as well as its current research status and potential future directions.
Introduction:
The cell cycle is a critical process that regulates the growth, development, and progression of all living organisms. The cell cycle is controlled by a complex network of genes, including those that encode non-coding RNAs (ncRNAs). One of these ncRNAs, LOC105374945, has been identified as a potential drug target and biomarker.
LOC105374945 is a non-coding RNA molecule that is highly conserved across various species and has been shown to play a critical role in regulating the cell cycle. It is a key regulator of the G1 phase, which is the stage of cell growth and preparation for cell division. LOC105374945 functions as a negative regulator of the cyclin D1 protein, which is involved in the G1 phase.
Disease associations:
The dysfunction of LOC105374945 has been linked to various diseases, including cancer. For example, LOC105374945 dysfunction has been associated with the development and progression of breast cancer. In addition, LOC105374945 has also been linked to the development of leukemia and other hematological cancers.
Potential drug targets:
LOC105374945 has been identified as a potential drug target due to its critical role in regulating the cell cycle. Many drugs that are currently in use, such as taxanes and vinca alkaloids, work by inhibiting the activity of cyclin D1. Therefore, LOC105374945 could be a useful target for new drugs that are designed to inhibit its function.
Biomarkers:
LOC105374945 has also been identified as a potential biomarker for various diseases, including cancer. Its dysfunction has been associated with the development and progression of cancer, and therefore, it could be a useful biomarker for monitoring the effectiveness of cancer treatments.
Research status:
Currently, there is limited research on LOC105374945, and much of the research that has been done on it is focused on its function in regulating the cell cycle. However, studies have shown that LOC105374945 is a conserved non-coding RNA molecule that plays a critical role in regulating the cell cycle.
Future directions:
In the future, there is potential for further research on LOC105374945 as a drug target and biomarker. For example, researchers could investigate the specific compounds that are currently in use and determine their effectiveness in inhibiting LOC105374945's function. Additionally, researchers could also investigate new compounds that are currently being developed and determine their potential as LOC105374945 inhibitors.
Conclusion:
LOC105374945 is a non-coding RNA molecule that has been identified as a potential drug target and biomarker. Its dysfunction has been linked to various diseases, including cancer, and its potential as a drug target and biomarker is currently being investigated. Further research is needed to fully understand its function and potential as a drug.
Protein Name: Uncharacterized LOC105374945
The "LOC105374945 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about LOC105374945 comprehensively, including but not limited to:
• general information;
• protein structure and compound binding;
• protein biological mechanisms;
• its importance;
• the target screening and validation;
• expression level;
• disease relevance;
• drug resistance;
• related combination drugs;
• pharmacochemistry experiments;
• related patent analysis;
• advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai
More Common Targets
LOC105374968 | LOC105374971 | LOC105374974 | LOC105374976 | LOC105374985 | LOC105374989 | LOC105375005 | LOC105375010 | LOC105375016 | LOC105375019 | LOC105375020 | LOC105375021 | LOC105375024 | LOC105375032 | LOC105375033 | LOC105375039 | LOC105375043 | LOC105375047 | LOC105375056 | LOC105375063 | LOC105375065 | LOC105375069 | LOC105375070 | LOC105375088 | LOC105375091 | LOC105375104 | LOC105375120 | LOC105375122 | LOC105375139 | LOC105375161 | LOC105375170 | LOC105375172 | LOC105375175 | LOC105375179 | LOC105375186 | LOC105375194 | LOC105375195 | LOC105375199 | LOC105375204 | LOC105375207 | LOC105375218 | LOC105375230 | LOC105375235 | LOC105375236 | LOC105375237 | LOC105375242 | LOC105375264 | LOC105375275 | LOC105375284 | LOC105375291 | LOC105375310 | LOC105375337 | LOC105375340 | LOC105375341 | LOC105375347 | LOC105375361 | LOC105375379 | LOC105375381 | LOC105375404 | LOC105375410 | LOC105375423 | LOC105375428 | LOC105375429 | LOC105375434 | LOC105375440 | LOC105375443 | LOC105375448 | LOC105375451 | LOC105375452 | LOC105375490 | LOC105375492 | LOC105375494 | LOC105375508 | LOC105375523 | LOC105375536 | LOC105375541 | LOC105375543 | LOC105375552 | LOC105375556 | LOC105375567 | LOC105375574 | LOC105375597 | LOC105375600 | LOC105375610 | LOC105375623 | LOC105375629 | LOC105375631 | LOC105375639 | LOC105375655 | LOC105375670 | LOC105375672 | LOC105375683 | LOC105375690 | LOC105375704 | LOC105375712 | LOC105375716 | LOC105375721 | LOC105375725 | LOC105375730 | LOC105375733
